loading...| Preferred Name |
paritaprevir |
|
| Synonyms |
ABT 450 |
|
| ID |
http://purl.bioontology.org/ontology/MESH/C585405 |
|
| altLabel |
ABT 450 ABT450 paritaprevir dihydrate (2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(E)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide veruprevir veruprevir anhydrous paritaprevir hydrate ABT-450 |
|
| cui |
C3883274 C3712108 C3864824 |
|
| Has mapping qualifier | ||
| HM |
D011392/Q000031 D047029 D003521 D013449 |
|
| II |
D000998 |
|
| Inverse of RB |
OU2YM37K86 HRQ5901O78 0 |
|
| Mapped to |
http://purl.bioontology.org/ontology/MESH/D013449 http://purl.bioontology.org/ontology/MESH/D047029 |
|
| MDA |
20140101 |
|
| MeSH Frequency |
297 |
|
| MMR |
20220812 |
|
| notation |
C585405 |
|
| prefLabel |
paritaprevir |
|
| RR |
HRQ5901O78 |
|
| SC |
1 |
|
| Scope Statement |
inhibits HCV NS3 protease |
|
| SRC |
World J Gastroenterol. 2013 Jun 7;19(21):3199-206. |
|
| TERMUI |
T852850 T001123448 T001123446 T001123449 T001123447 T000877905 T001123450 T001092945 T001092944 |
|
| TH |
FDA SRS (2017) NLM (2015) NLM (2022) NLM (2021) USAN (19XX) INN (19XX) NLM (2014) |
|
| tui |
T109 T121 |